Please assess the completion status of the following clinical trial:

Trial Title: Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>18 years~* With well compensated cirrhosis and hepatocellular carcinoma meeting UCSF criteria~* Without general contraindication to LT~* Written informed consent.~Exclusion Criteria:~* Patients that already had TACE~* Or other local treatment for HCC~* Or neoadjuvant systemic chemotherapy~* Or planned living donor~* Or non arterialized lesion(s)~* Or Contraindication to DC-BeadsR~* Or allergy to contrast agents~* Or contraindication to Doxorubicin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-arterial administration of DC BeadsR (Type: EXPERIMENTAL): Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
- Control (Type: NO_INTERVENTION): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).